Muscle Fatigue and Carbonic Anhydrase Inhibitors

University of British Columbia

Status and phase: Completed; Phase 4

Conditions: Hypoxia

Treatments: Drug: Acetazolamide; Drug: Methazolamide; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02758470

H16-00896

Details and patient eligibility

About

The objective of this research is to assess the effects of acetazolamide and methazolamide on respiratory and limb muscle fatigue development. A fatiguing protocol will be conducted for the respiratory and plantar flexor muscles and the difference in pressure/torque produced by supramaximal nerve stimulation used to assess muscle fatigue between conditions.

Enrollment: 13 patients

Sex: Male

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age: 18-40 years.
• Regularly physically active
• Male

Exclusion criteria

• current or ex-smokers
• pulmonary function <80% of predicted
• esophageal tumour or ulcer
• have had recent (<6 months) musculoskeletal injury or any surgery to the lower leg
• have contraindications to carbonic anhydrase inhibitors (eg. severe or absolute glaucoma, adrenocortical insufficiency, hepatic insufficiency, renal insufficiency, sulfa allergy or an electrolyte imbalance such as hyperchloremic acidosis)
• are obese (BMI >30 Kg/m2)
• taking diuretics, blood thinners, or anti-platelet drugs.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

13 participants in 3 patient groups, including a placebo group

Acetazolamide

Experimental group

Description:

Participants will be dosed 250mg acetazolamide (p.o.) three times per day for two days prior to and a single dose on the morning of the experimental day.

Treatment:

Drug: Acetazolamide

Methazolamide

Experimental group

Description:

Participants will be dosed 100mg Methazolamide (p.o.) two times per day separated by a placebo dose for two days prior to and a single dose on the morning of the experimental day. The placebo dose is used to match the timing and number of pills taken between all arms of the study.

Treatment:

Drug: Methazolamide

Placebo

Placebo Comparator group

Description:

Participants will take three placebo pills per day for two days prior to and a single dose on the morning of the experimental day.

Treatment:

Other: Placebo